Controversial figure Ramdev's Patanjali accused a "mafia" following the alleged ban on five of their medicines in Uttarakhand.

In a recent development, the Uttarakhand government has taken action against Patanjali Ayurved Ltd., outlawing the production of five of its medicines. The decision was made following a public interest litigation (PIL) that challenged the safety and efficacy claims of these medicines.

The action was initiated in response to a complaint filed by Kerala-based eye doctor KV Babu in July this year. The Ayurveda and Unani Licensing Authority in Dehradun, Uttarakhand, has ordered Divya Pharmacy, a subsidiary of Patanjali Ayurved Ltd., to stop production of Madhugrit, Eyegrit, Thyrogrit, BPgrit, and Lipidom, which are part of Patanjali's ayurveda health products.

The order, issued by Dr GCS. Jangpangi, certificate police officer, Uttarakhand Ayurvedic and Unani Providers, accuses Patanjali of deceptive promotions. However, the order does not specify the details of the allegations against the five products in question.

In a statement, Patanjali Ayurved Ltd. has stated that it has not received a copy of the order mentioned in the reports. The company also claims that it has not been provided with details about the specific allegations against the five products.

Patanjali employs over 500 scientists to ensure high research and quality in Ayurveda practice. The company has also stated that all its products and medicines are made following recommended guidelines, meeting all legal procedures and global standards.

The company's pharmaceutical arm, Divya Drug store, has implicated an "anti-Ayurveda medication mafia" of a conspiracy. If the department does not remedy the error or penalize those involved in the conspiracy and compensate for institutional loss, Patanjali has threatened to take legal action.

This latest development is the latest chapter in the ongoing controversy surrounding Patanjali's pharmaceutical company and its products. The company has faced criticism and scrutiny in the past over its advertising practices and the efficacy of its products.

The reports stated that the action was taken based on KV Babu's complaints. However, the identity of the individuals involved in the complaint remains unknown. The Hindustan Times reported that the action was taken following a letter written and circulated in the media on 09.11.2022, which has not been provided to Patanjali Sansthan until now.

Patanjali's medicines, which are promoted as therapies for hypertension, diabetes, lumps, glaucoma, and high cholesterol, have been a popular choice among consumers due to their alleged natural ingredients and Ayurvedic practices. The ban on the production of these five medicines could have significant implications for the company and its customers.

As the situation unfolds, Patanjali Ayurved Ltd. has vowed to fight the allegations and take legal action if necessary. The company maintains that all its products and medicines are made following recommended guidelines, meeting all legal procedures and global standards. The controversy surrounding Patanjali's pharmaceutical company and its products is likely to continue in the coming days and weeks.